Eli Lilly will now sell cheaper vials of Zepbound, presenting a direct challenge to telehealth companies that offer compounded versions of the...

Does Eli Lilly (LLY) have what it takes to be a top stock pick for momentum investors? Let's find out.

Does Eli Lilly (LLY) have what it takes to be a top stock pick for momentum investors? Let's find out.

VKTX's shares fell after rival Eli Lilly announced that it is launching cheaper versions of Zepbound to strengthen its presence in the obesity market.

Eli Lilly and Co. is now selling vials of its blockbuster weight-loss drug Zepbound to patients for as little as $399 a month as it works to overcome...

Eli Lilly and Co. is now selling vials of its blockbuster weight-loss drug Zepbound to patients for as little as $399 a month as it works to overcome...

Broadcom shares tumble as revenue outlook fails to impress investors. Is it the right time to sell the AVGO stock, or will remaining bullish be...

Broadcom shares tumble as revenue outlook fails to impress investors. Is it the right time to sell the AVGO stock, or will remaining bullish be...

TUESDAY, Aug. 27, 2024 -- Eli Lilly, maker of one of the blockbuster GLP-1 weight-loss drug Zepbound, says it will now offer the medication in...

Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.